Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Medtronic's Marketable Securities for the quarter that ended in Apr. 2026 was R$36,601 Mil.
Medtronic's annual Marketable Securities
increased
from Apr. 2024 (R$34,479 Mil) to Apr. 2025 (R$39,069 Mil) but then
declined
from Apr. 2025 (R$39,069 Mil) to Apr. 2026 (R$36,601 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Medtronic Marketable Securities Related Terms
Medtronic Marketable Securities Historical Data
* Premium members only.
The historical data trend for Medtronic's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of R$36,601 Mil mean?
Medtronic (BSP:MDTC34) has a Marketable Securities of R$36,601 Mil as of Apr. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medtronic and its competitors.
Is Medtronic's Marketable Securities too high?
Medtronic's current Marketable Securities is R$36,601 Mil. Overall, Medtronic has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Marketable Securities compare to SYK and BSX?
Medtronic's Marketable Securities of R$36,601 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medtronic and its competitors. Medtronic's current Marketable Securities is R$36,601 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$62.00, compared to a current price of R$52.47 — trading 15.4% below its estimated fair value. The current Marketable Securities is R$36,601 Mil. Medtronic's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Marketable Securities is R$36,601 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$52.47 is trading 15.4% below its estimated GF Value™ of R$62.00.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for BSP:MDTC34:
Marketable Securities: R$36,601 Mil
GF Value™: R$62.00 vs. price of R$52.47 (15.4% below fair value)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
67GF Score
Get the complete analysis for BSP:MDTC34
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
